ArticleJournal of clinical medicine research2025
Assessment of the Treatment for Alcohol Withdrawal Syndrome With and Without Dexmedetomidine: A Retrospective Cohort Study.
Article in Journal of clinical medicine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dexmedetomidine in The Treatment of Toxicologic Conditions in The Emergency Department: A Dual-Center Retrospective Observational Cohort Study.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alcohol withdrawal syndrome (AWS) carries a high risk of morbidity and mortality that often requires critical care admission and monitoring. Dexmedetomidine is a known sedative that can help with patient symptoms and potentially reduce Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar) scores. This study looks at two groups - the use of dexmedetomidine versus non-dexmedetomidine - in the management of AWS patients to assess the length of intensive care unit (ICU) stay, length of stay (LOS) in hospital, mortality and readmission rate. Methods: This retrospective cohort study was conducted at Geisinger Health System, a tertiary care, academic health care system, between January 2016 and December 2022. This study did not require ethics approval according to the Institutional Review Board (IRB). The patients assessed included those aged 18 years or older with a documented CIWA-Ar score requiring admission to the ICU or ICU step-down unit. Exclusion criteria included ICU admission for alternative indications, a prior history of seizure disorder, or patients who left against medical advice. Results: A total of 994 patients were identified to have met the inclusion criteria; 371 patients were in the non-dexmedetomidine group and 623 in the dexmedetomidine group. Primary outcomes assessed were hospital LOS (5.0 (3.0 - 9.0) vs. 10 (6.0 - 16.0), P < 0.0001) and days in the ICU (1.9 (1.0 - 3.4) vs. 4.9 (2.9 - 9.0), P < 0.0001), respectively. Secondary outcomes assessed were lorazepam equivalent usage, and readmission within 30, 60 and 90 days, which were not statistically significant when accounting for ICU LOS. Conclusions: Among patients treated for AWS, dexmedetomidine use appeared to be associated with longer hospital and ICU stays, while benzodiazepine requirements remained unchanged. These associations may reflect differences in illness severity, emphasizing the need for future prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.